Chemaphor Inc.: Interest in Oximunol (TM) Chewable Tablets Strong at Ontario Association of Veterinary Technicians Conference

Chemaphor Inc.(TSX VENTURE:CFR) At the recent Ontario Association of Veterinary
Technicians (OAVT) Conference held in London, Ontario, about 1000 veterinary
technicians were introduced to Avivagen Animal Health Inc. ("Avivagen") and its
new products Oximunol(TM) Chewable Tablets and VetStem RC Regenerative Cell
Therapy. 


"Our participation in this tradeshow produced hundreds of leads from veterinary
technicians interested in Oximunol(TM) Chewable Tablets and VetStem RC
Regenerative Cell Therapy," said Kira Andersen, sales representative with
Avivagen Animal Health. "We are going to be very busy following up with all
those clinics in the coming weeks." About 250 technicians took time to talk at
length with the Avivagen reps and sign up for a free draw for two pet baskets
and a number of 50-day bottles of Oximunol(TM) Chewable Tablets to try on their
own dogs. 


 "I am most definitely interested in trying Oximunol(TM) Chewable Tablets on my
15 year old Jack Russell after learning about it," said Nicole Swartzentruber, a
registered veterinary technician with Embro Veterinary Services in Embro,
Ontario. "If I see results in his mobility and overall health, I will definitely
tell the veterinarians I work with about it."


The OAVT Conference was the first of numerous key tradeshows planned this year
for Avivagen. Other major tradeshows booked include the American Animal Hospital
Association/Ontario Veterinary Medical Association Conference in Toronto, ON,
the Association des medecins veterinaries du Quebec, in Saint-Hyacinthe, QC, the
Canadian Veterinary Medical Association Conference in Halifax, NS, the Animal
Health Technologists Association of British Columbia Conference in Kamloops, BC
and the CanWest Veterinary Conference in Banff, AB.


Oximunol(TM) Chewable Tablets contain OxC-beta, a fully oxidized form of
ss-carotene, that is made up of compounds occurring naturally in the plant
world. These compounds offer significant health benefits to dogs in a palatable,
chewable daily tablet. Canadian clinical trials have shown a statistically
significant improvement in coat quality, including a reduction of shedding.
Oximunol(TM) Chewable Tablets also help dogs enjoy activity more and help
optimize normal gastrointestinal and general health, especially in older and
less active dogs.


VetStem RC Regenerative Cell Therapy is scientifically proven for treatment of
arthritic conditions, and joint and ligament injuries in dogs, cats and horses.
The therapy uses regenerative cells derived from an animal's own adipose tissue.
A small amount of fat tissue is extracted by the patient's veterinarian, and
then couriered to Avivagen Animal Health's new, state-of-the-art, Canadian
laboratory facility in Charlottetown, PEI. The cells are processed and counted,
following stringent sterility and quality assurance guidelines. The doses
required for immediate treatment are then returned to the veterinarian for
injection into the patient, often within 48 hours of extraction. Extra doses are
stored by Avivagen Animal Health for future treatments. 


Avivagen is a new Canadian company dedicated to improving the quality of life of
animals through science-based, natural health products proven in clinical trials
and sold exclusively through veterinarians. Avivagen is a subsidiary of
Chemaphor Inc., a Canadian company dedicated to the research and development of
science-based, natural products for people and animals. VetStem RC Regenerative
Cell Therapy has been exclusively licensed by Avivagen for the Canadian animal
health market from Vet-Stem (USA).


Chemaphor is a publicly traded company listed on the (TSX VENTURE:CFR).

(TM) Trademark of Chemaphor Inc. VetStem RC Regenerative Cell Therapy is
licensed from Vet-Stem, Inc. 


Forward Looking Statements

This news release includes certain forward-looking statements that are based
upon current expectations, which involve risks and uncertainties associated with
the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the
environment in which their respective businesses operate. Any statements
contained herein that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions "will",
"anticipate", "believe", "plan", "estimate", "expect", "intend", and similar
expressions. The forward-looking statements reflect the current expectations of
Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or
events. These forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ materially
from current expectations. Chemaphor assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those reflected in the forward-looking statements. The results of
treatment described above are based on historical results. Different animals may
experience different results from the treatments described above. Anyone
interested in the treatments described above should discuss the potential
benefits and risks of such treatments with their veterinarian.
Chemaphor Inc. (TSXV:CFR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024